Global Reproductive Genetics Market, by Product Type (Kits, Laboratory Developed Tests, Reagents & Consumables), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In-Situ Hybridization, Microarray), By Application (Aneuploidy, Structural Chromosomal Abnormality, Single Gene Disorder, Other Applications), and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Reproductive Genetics Market Overview

The global reproductive genetics market is projected to reach a valuation of USD 15,904.46 Mn by 2031 at a CAGR of 12.30%, from USD 4,985.65 Mn in 2021.

Market.US announces the publication of a recently generated research report titled, “Global Reproductive Genetics Market, by Procedure Type (Carrier Screening, Pre-Natal Screening, Pre-Implantation Genetic Testing, Infertility Genetic Testing) by Product Type (Kits, Laboratory Developed Tests, Reagents & Consumables), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In-Situ Hybridization, Microarray), By Application (Aneuploidy, Structural Chromosomal Abnormality, Single Gene Disorder, Other Applications), and by Region – Global Forecast to 2031”. This report offers a holistic view of the global reproductive genetics market through systematic segmentation that covers every aspect of the target market.

Reproductive genetics is the study of genes that affect reproduction. This includes the genes that control how often a person reproduces, the number of children they have, and the sex of their children. Reproductive genetics also includes the study of genes that can cause birth defects. In reproductive genetics, several tests can be performed on an embryo to determine if it is healthy and has the potential to result in a successful pregnancy. Pre-Implantation Genetic Diagnosis (PGD) is one such test. This test is typically used when a couple is at risk of passing on a genetic disorder to their child. The field of reproductive genetics is relatively new but rapidly growing. This area of study focuses on the genetic aspects of reproduction. Reproductive genetics can be used to help couples who are struggling to conceive a child. It can also screen embryos for genetic disorders before they are implanted in the womb. It covers the study of both the male and female gametes and the embryo. Reproductive genetics diagnose and treat disorders that may affect fertility or embryo development.

In reproductive genetics, scientists are constantly working on new ways to improve fertility and prevent genetic disorders. In recent years, they have made great strides in developing treatments for infertility and screening tests for genetic abnormalities. One of the most exciting developments in this field is in-vitro fertilization (IVF), which has helped many couples conceive children who would not have been able to otherwise.

There are some disadvantages to this type of genetics. One disadvantage is that it can be expensive. Another disadvantage is that it can be a complicated process.

The Global Reproductive Genetics Market Revenue (US$ Mn), 2021–2031

Source: Prudour, 2021

Reproductive genetics aids in identifying the reason for infertility and carriers of genetic illnesses, allowing for the most appropriate assisted reproductive procedures to be implemented. As a result, these factors are expected to propel the future global reproductive genetics market forward. Increasing literacy rates have resulted in a spike in public awareness of personal genetic risks, influencing public opinion and interest worldwide. In addition, increased public participation in personal genomics activities, such as research and genomic services, has also increased public knowledge and comprehension of genetics. Furthermore, in recent years, various government-sponsored training programs and the increase in Direct-To-Consumer (DTC) testing have augmented public awareness of genetic healthcare. These factors are anticipated to further contribute to this market in the coming years.

Various regulatory organizations worldwide have placed restrictions on the use of reproductive genetics tests, fearing that the increased usage of Pre-Natal testing will increase the number of abortions. As a result, professional organizations such as the American College of Obstetricians and Gynecologists (ACOG), the International Society for Pre-Natal Diagnosis, the United States National Society of Genetic Counselors (NSGC), and the Japan Society of Obstetrics and Gynecology have established a few guidelines to limit the use of non-invasive prenatal testing to pregnant women at high risk of chromosomal aneuploidies, which in turn is expected to hinder the overall revenue growth of this market.

Following the onset of the COVID-19 pandemic, respective governments implemented strict restrictions on the movement of individuals and clinic closures. The broader healthcare system was also impacted by a shortage of competent human resources, infrastructure discrepancies, and logistical challenges. The situation worsened further due to a global shutdown, which resulted in reduced access and a decline in genetic testing.

Reproductive genetic testing companies, on the other hand, adopted various strategies, including supply chain consolidation, to recoup from the pandemic’s losses. As a result, this market is expected to resume its projected growth trajectory over the next decade.

This research report on the global reproductive genetics market includes major company profiles such as

• Agilent Technologies Inc.
• BGI, CENTOGENE AG
• Fulgent Genetics Inc.
• F. Hoffmann-La Roche Ltd
• Igenomix
• Illumina Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• PerkinElmer Inc.
• Myriad Genetics Inc.
• OPKO Health Inc.
• Quest Diagnostics
• QIAGEN N.V.
• Thermo Fisher Scientific Inc., among others.

In March 2020, Agilent Technology announced the release of three new microarrays for prenatal and postnatal research. The microarray comprises clinically useful content that has been updated from reputable databases. New gene-disease connections are discovered as next-generation sequencing advances, and databases are continually evolving to integrate these findings.

In May 2021, Juno Diagnostics, a startup focusing on improving access to genetic health information, announced the closure of a US$25 million Series-A fundraising round headed by the Perceptive Xontogeny Venture (PVX) fund. The funding will assist JunoDx’s non-invasive prenatal diagnostic product development, clinical validation studies, and commercial launch.

The Global Reproductive Genetics Market Segmentation is Based on Procedure Type, Product Type, Technology, Application, and Region

Based on Procedure Type

• Carrier Screening
• Pre-Natal Screening
• Pre-Implantation Genetic Testing
• Infertility Genetic Testing

Based on Product Type

• Kits
• Laboratory Developed Tests
• Reagents & Consumables

Based on Technology

• Next Generation Sequencing
• Polymerase Chain Reaction
• In-Situ Hybridization
• Microarray

Based on Application

• Aneuploidy
• Structural Chromosomal Abnormality
• Single Gene Disorder
• Other Applications

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For the Reproductive Genetics Market research study, the following years have been considered to estimate the market size: